Rafael is offering its Jam-Air directional
infra-red countermeasures anti-missile system for
use on small, slow aircraft.
The Jam-Air was originally developed to protect
helicopters but according to lova Drori, Rafael's
vice-president of marketing, the system can be
installed on small aircraft that fly relatively
slowly.
The Israeli air force has begun equipping its
helicopters with the Jam-Air.The system is
replacing the AN/ALQ-144, an omni-directional
active infra-red countermeasures system, which
according to the the IAF is no longer sufficient
for current threats.
The Jam-Air is housed in a gimballed turret and
based on an arc lamp technology that produces a
wide beam that jams the IR seeker of the missile
by disengaging the sensor's lock on the heat
source..
Rafael says the 30kg Jam-Air can be installed on
any part of the helicopter and that its wide beam
more efficient than a directed very narrow laser
beam.
Teva predicts $10.75 billion revenue in 2008
Teva CEO Shlomo Yanai predicts that the adjusted
earnings per share will exceed $3 in 2009.
Teva added that it now has 160 product
applications waiting for US Food and Drug
Administration (FDA) approval. The brand products
have $100 billion in annual sales. The company
added that it believes that it is the first to
file on 49 of these products, and that it expects
to continue obtaining an average of 12 FDA
approvals a year. In addition, the company has
166 applications pending approval.
Teva Pharmaceutical Industries Ltd. (Nasdaq:
TEVA; TASE: TEVA) predicts $10.75 billion and
non-GAAP earnings per share of $2.60-2.75 in
2008. The guidance is above the market consensus
of $10.41 billion revenue, although in line with
earnings per share of $2.67.